Literature DB >> 7608534

Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase.

P Benveniste1, W Zhu, A Cohen.   

Abstract

Adenosine deaminase (ADA) deficiency causes severe combined immune-deficiency disease in humans. It is believed that the accumulation of the ADA substrate deoxyadenosine affects T cell development through interference with deoxynucleotide metabolism and/or S-adenosylmethionine-mediated methylation processes. In this study, we used a specific inhibitor of methylation, (Z)-5'-fluoro-4',5'-didehydro-5'-deoxyadenosine (FddA), to study the effect of inhibition of methylation on intrathymic T cell development in a murine model for ADA deficiency. FddA causes inhibition of thymocyte differentiation specifically at the CD8low and CD4CD8 double-positive stages. This inhibition is not due to induction of apoptosis, rather it is a result of specific inhibition of regulation of the levels of the mRNAs coding for TCR and CD4 and CD8 co-receptor molecules that normally occurs at these stages of thymocyte differentiation. We hypothesize that the transcription of these T cell-specific molecules is regulated by a common developmental stimulus involving a S-adenosylmethionine-mediated methylation step. Identification of this step will help in understanding the role of methylation in intrathymic differentiation and will also provide a molecular explanation for the tissue and developmental stage specificity observed in severe combined-immune-deficient patients with ADA deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608534

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Severe combined immunodeficiency--molecular pathogenesis and diagnosis.

Authors:  H B Gaspar; K C Gilmour; A M Jones
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

2.  Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling.

Authors:  S G Apasov; M R Blackburn; R E Kellems; P T Smith; M V Sitkovsky
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 3.  Transmethylation in immunity and autoimmunity.

Authors:  Brian R Lawson; Theodoros Eleftheriadis; Virginie Tardif; Rosana Gonzalez-Quintial; Roberto Baccala; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Clin Immunol       Date:  2011-12-24       Impact factor: 3.969

Review 4.  Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?

Authors:  Benjamin Hall; Jonathan G George; Scott P Allen
Journal:  Histol Histopathol       Date:  2021-12-09       Impact factor: 2.303

Review 5.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

Review 6.  How I treat ADA deficiency.

Authors:  H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

7.  Restoration of adenosine deaminase-deficient human thymocyte development in vitro by inhibition of deoxynucleoside kinases.

Authors:  Michelle L Joachims; Patrick A Marble; Aletha B Laurent; Peter Pastuszko; Marco Paliotta; Michael R Blackburn; Linda F Thompson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.

Authors:  Aisha Vanessa Sauer; Immacolata Brigida; Nicola Carriglio; Alessandro Aiuti
Journal:  Front Immunol       Date:  2012-08-27       Impact factor: 7.561

9.  Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction.

Authors:  M R Blackburn; J B Volmer; J L Thrasher; H Zhong; J R Crosby; J J Lee; R E Kellems
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

Review 10.  Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.

Authors:  Claudia A Montiel-Equihua; Adrian J Thrasher; H Bobby Gaspar
Journal:  Stem Cells Cloning       Date:  2009-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.